Clarifying the impact of polycomb complex component disruption in human cancers

Area of Science:

• Epigenetics and Cancer Biology
• Transcriptional Regulation
• Chromatin Modification

Background:

• Dysregulated transcriptional control is a key driver of developmental diseases and cancers.
• Polycomb proteins, including the BCOR complex (BCOR, RNF2, PCGF1, KDM2B), regulate gene silencing via chromatin modification.
• The BCOR complex targets nonmethylated CpG islands, removing H3K36me2 and inducing H2A monoubiquitylation.

Purpose of the Study:

• To highlight the significance of BCOR and BCORL1 mutations and fusion transcripts in human cancers.
• To discuss the diagnostic and prognostic implications of these genetic alterations.
• To emphasize the need for further functional studies to elucidate oncogenic mechanisms and develop novel therapeutics.

Main Methods:

• Review of existing literature and sequencing data identifying BCOR and BCORL1 alterations.
• Analysis of the role of BCOR complex in transcriptional silencing.
• Correlation of genetic findings with clinical outcomes in cancer patients.

Main Results:

• Germline BCOR mutations are associated with oculofaciocardiodental and Lenz microphthalmia syndromes.
• BCOR and BCORL1 chimeric fusion transcripts are found in various cancers (e.g., leukemia, sarcoma, HCC).
• Inactivating somatic BCOR and BCORL1 mutations are identified in AML, MDS, medulloblastoma, and retinoblastoma, with BCOR mutations correlating with poor prognosis in AML/MDS.

Conclusions:

• BCOR and BCORL1 alterations are crucial biomarkers for cancer diagnosis and predicting treatment response.
• Understanding the oncogenic mechanisms of BCOR/BCORL1 disruption is essential for targeted therapy development.
• Further functional studies are warranted to fully elucidate the role of BCOR and BCORL1 in oncogenesis.